333 related articles for article (PubMed ID: 20858716)
1. PALB2/FANCN: recombining cancer and Fanconi anemia.
Tischkowitz M; Xia B
Cancer Res; 2010 Oct; 70(19):7353-9. PubMed ID: 20858716
[TBL] [Abstract][Full Text] [Related]
2. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
Reid S; Schindler D; Hanenberg H; Barker K; Hanks S; Kalb R; Neveling K; Kelly P; Seal S; Freund M; Wurm M; Batish SD; Lach FP; Yetgin S; Neitzel H; Ariffin H; Tischkowitz M; Mathew CG; Auerbach AD; Rahman N
Nat Genet; 2007 Feb; 39(2):162-4. PubMed ID: 17200671
[TBL] [Abstract][Full Text] [Related]
3. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Rahman N; Seal S; Thompson D; Kelly P; Renwick A; Elliott A; Reid S; Spanova K; Barfoot R; Chagtai T; Jayatilake H; McGuffog L; Hanks S; Evans DG; Eccles D; ; Easton DF; Stratton MR
Nat Genet; 2007 Feb; 39(2):165-7. PubMed ID: 17200668
[TBL] [Abstract][Full Text] [Related]
4. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
[TBL] [Abstract][Full Text] [Related]
5. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
Nepomuceno TC; De Gregoriis G; de Oliveira FMB; Suarez-Kurtz G; Monteiro AN; Carvalho MA
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858227
[TBL] [Abstract][Full Text] [Related]
6. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.
Xia B; Dorsman JC; Ameziane N; de Vries Y; Rooimans MA; Sheng Q; Pals G; Errami A; Gluckman E; Llera J; Wang W; Livingston DM; Joenje H; de Winter JP
Nat Genet; 2007 Feb; 39(2):159-61. PubMed ID: 17200672
[TBL] [Abstract][Full Text] [Related]
7. Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Park D; Bergin SM; Jones D; Ru P; Koivisto CS; Jeon YJ; Sizemore GM; Kladney RD; Hadjis A; Shakya R; Ludwig T
Cancer Res; 2020 Oct; 80(19):4172-4184. PubMed ID: 32732220
[TBL] [Abstract][Full Text] [Related]
8. Analysis of PALB2/FANCN-associated breast cancer families.
Tischkowitz M; Xia B; Sabbaghian N; Reis-Filho JS; Hamel N; Li G; van Beers EH; Li L; Khalil T; Quenneville LA; Omeroglu A; Poll A; Lepage P; Wong N; Nederlof PM; Ashworth A; Tonin PN; Narod SA; Livingston DM; Foulkes WD
Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6788-93. PubMed ID: 17420451
[TBL] [Abstract][Full Text] [Related]
9. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
[TBL] [Abstract][Full Text] [Related]
10. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
11. Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).
McReynolds LJ; Biswas K; Giri N; Sharan SK; Alter BP
Cancer Genet; 2021 Nov; 258-259():101-109. PubMed ID: 34687993
[TBL] [Abstract][Full Text] [Related]
12. Assessment of PALB2 as a candidate melanoma susceptibility gene.
Aoude LG; Xu M; Zhao ZZ; Kovacs M; Palmer JM; Johansson P; Symmons J; Trent JM; Martin NG; Montgomery GW; Brown KM; Hayward NK
PLoS One; 2014; 9(6):e100683. PubMed ID: 24949998
[TBL] [Abstract][Full Text] [Related]
13. [PALB2 as Another Candidate Gene for Genetic Testing in Patients with Hereditary Breast Cancer in Czech Republic].
Janatová M; Borecká M; Soukupová J; Kleiblová P; Stříbrná J; Vočka M; Zemánková P; Panczak A; Veselá K; Souček P; Foretová L; Kleibl Z
Klin Onkol; 2016; 29 Suppl 1():S31-4. PubMed ID: 26691940
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
[TBL] [Abstract][Full Text] [Related]
15. PALB2 mutations in familial breast and pancreatic cancer.
Hofstatter EW; Domchek SM; Miron A; Garber J; Wang M; Componeschi K; Boghossian L; Miron PL; Nathanson KL; Tung N
Fam Cancer; 2011 Jun; 10(2):225-31. PubMed ID: 21365267
[TBL] [Abstract][Full Text] [Related]
16. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
[TBL] [Abstract][Full Text] [Related]
18. Exploring the link between MORF4L1 and risk of breast cancer.
Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
20. Novel germline PALB2 truncating mutations in African American breast cancer patients.
Zheng Y; Zhang J; Niu Q; Huo D; Olopade OI
Cancer; 2012 Mar; 118(5):1362-70. PubMed ID: 21932393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]